JP2022515193A5 - - Google Patents

Info

Publication number
JP2022515193A5
JP2022515193A5 JP2021536024A JP2021536024A JP2022515193A5 JP 2022515193 A5 JP2022515193 A5 JP 2022515193A5 JP 2021536024 A JP2021536024 A JP 2021536024A JP 2021536024 A JP2021536024 A JP 2021536024A JP 2022515193 A5 JP2022515193 A5 JP 2022515193A5
Authority
JP
Japan
Prior art keywords
nucleotides
nucleotide
app
double
rnai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021536024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067449 external-priority patent/WO2020132227A2/en
Publication of JP2022515193A publication Critical patent/JP2022515193A/ja
Publication of JP2022515193A5 publication Critical patent/JP2022515193A5/ja
Priority to JP2024090554A priority Critical patent/JP2024113043A/ja
Pending legal-status Critical Current

Links

JP2021536024A 2018-12-19 2019-12-19 アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 Pending JP2022515193A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024090554A JP2024113043A (ja) 2018-12-19 2024-06-04 アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862781774P 2018-12-19 2018-12-19
US62/781,774 2018-12-19
US201962862472P 2019-06-17 2019-06-17
US62/862,472 2019-06-17
US201962928795P 2019-10-31 2019-10-31
US62/928,795 2019-10-31
PCT/US2019/067449 WO2020132227A2 (en) 2018-12-19 2019-12-19 AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090554A Division JP2024113043A (ja) 2018-12-19 2024-06-04 アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2022515193A JP2022515193A (ja) 2022-02-17
JP2022515193A5 true JP2022515193A5 (cg-RX-API-DMAC7.html) 2022-12-26

Family

ID=71101909

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021536024A Pending JP2022515193A (ja) 2018-12-19 2019-12-19 アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法
JP2024090554A Pending JP2024113043A (ja) 2018-12-19 2024-06-04 アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024090554A Pending JP2024113043A (ja) 2018-12-19 2024-06-04 アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法

Country Status (20)

Country Link
US (2) US11034957B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898979A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022515193A (cg-RX-API-DMAC7.html)
KR (1) KR20210111780A (cg-RX-API-DMAC7.html)
CN (2) CN113454222B (cg-RX-API-DMAC7.html)
AU (2) AU2019405783B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011895A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124090A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001605A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009163A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210393A (cg-RX-API-DMAC7.html)
DO (2) DOP2021000126A (cg-RX-API-DMAC7.html)
IL (1) IL283852A (cg-RX-API-DMAC7.html)
MX (1) MX2021007570A (cg-RX-API-DMAC7.html)
MY (1) MY206230A (cg-RX-API-DMAC7.html)
PE (1) PE20211420A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551482A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105886QA (cg-RX-API-DMAC7.html)
TW (1) TW202039844A (cg-RX-API-DMAC7.html)
WO (1) WO2020132227A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2854880B1 (en) 2012-05-29 2019-03-13 3M Innovative Properties Company Absorbent article comprising polymeric foam
WO2019169243A1 (en) 2018-03-02 2019-09-06 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
WO2021012082A1 (zh) * 2019-07-19 2021-01-28 莫丁丁 β—淀粉样蛋白环状核糖核酸、多肽及其应用
JP2019213978A (ja) * 2019-09-30 2019-12-19 株式会社三洋物産 遊技機
MX2023001222A (es) 2020-07-28 2023-04-26 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de app.
US20240294906A1 (en) * 2020-07-29 2024-09-05 Alnylam Pharmaceuticals, Inc. Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases
WO2022165172A1 (en) * 2021-01-29 2022-08-04 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing amyloid precursor protein (app)
US20240175028A1 (en) * 2021-03-05 2024-05-30 Alnylam Pharmaceuticals, Inc DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA
JP2024518564A (ja) * 2021-05-11 2024-05-01 ディセルナ ファーマシューティカルズ インコーポレイテッド 中枢神経系のニューロンを標的とするための脂質コンジュゲーション
WO2023283403A2 (en) * 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
JP2024534961A (ja) * 2021-09-10 2024-09-26 アルナイラム ファーマシューティカルズ, インコーポレイテッド 拡大したエンドソームによって特徴付けられる疾患を処置または予防するためのAPP iRNA組成物およびその使用方法
KR20240067943A (ko) 2021-09-24 2024-05-17 알닐람 파마슈티칼스 인코포레이티드 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
JP2024542125A (ja) * 2021-10-28 2024-11-13 ザ・ホンコン・ユニバーシティー・オブ・サイエンス・アンド・テクノロジー アミロイド病変に対する治療アプローチとしてのapp発現のcrispr媒介性操作
WO2023081500A2 (en) * 2021-11-08 2023-05-11 Dicerna Pharmaceuticals, Inc. RNAi OLIGONUCLEOTIDE CONJUGATES
TW202335674A (zh) * 2021-11-05 2023-09-16 美商黛瑟納製藥公司 靶定中樞神經系統的星狀細胞之脂質結合物
TW202340462A (zh) * 2021-11-05 2023-10-16 美商黛瑟納製藥公司 靶定中樞神經系統的寡樹突細胞之脂質結合物
US20230392146A1 (en) * 2022-03-11 2023-12-07 University Of Massachusetts Oligonucleotides for app modulation
WO2023207615A1 (zh) * 2022-04-26 2023-11-02 南京明德新药研发有限公司 一类含由天然核苷酸组成突出端的双链RNAi化合物
WO2023224979A1 (en) * 2022-05-16 2023-11-23 University Of Massachusetts Optimized sirna scaffolds
WO2023230465A1 (en) * 2022-05-23 2023-11-30 Switch Therapeutics Inc. Antisense oligonucleotides
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
WO2025007961A1 (zh) 2023-07-06 2025-01-09 大睿生物 调控AGT表达的dsRNA分子
US20250064958A1 (en) * 2023-08-22 2025-02-27 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
WO2025045195A1 (zh) * 2023-08-31 2025-03-06 上海拓界生物医药科技有限公司 靶向APP的RNAi剂及其医药用途
CN120077136A (zh) * 2023-09-28 2025-05-30 广州必贝特医药股份有限公司 抑制淀粉样前体蛋白(APP)基因表达的siRNA、药物及其应用
TW202516009A (zh) * 2023-10-10 2025-04-16 大陸商上海舶望製藥有限公司 抑制澱粉樣前體蛋白(app)表達的組合物和方法
WO2025228429A1 (zh) * 2024-04-30 2025-11-06 北京安龙生物医药有限公司 靶向淀粉样前体蛋白基因的寡核苷酸及其用途
CN118979036B (zh) * 2024-08-01 2025-08-19 北京尧景基因技术有限公司 抑制APP基因表达的siRNA及其缀合物和应用
CN121175422A (zh) * 2024-10-08 2025-12-19 北京安龙生物医药有限公司 修饰的双链寡核苷酸及其缀合物和组合物
WO2026085164A2 (en) 2024-10-16 2026-04-23 Alnylam Pharmaceuticals, Inc. Snca irna formulations and methods of use thereof
WO2026092658A2 (en) * 2024-10-31 2026-05-07 Sanegene Bio Usa Inc. Small interfering rna targeting amyloid beta precursor protein (app) and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
CA2489174C (en) 2002-07-10 2013-02-05 Thomas Tuschl Rna-interference by single-stranded rna molecules
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
CA2528963A1 (en) * 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
GB0324854D0 (en) * 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
EP2239328A3 (en) * 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
JP5252622B2 (ja) * 2007-01-17 2013-07-31 独立行政法人産業技術総合研究所 高いヌクレアーゼ耐性と優れたrna干渉効果を発現可能な二本鎖rna
WO2009113579A1 (ja) * 2008-03-11 2009-09-17 学校法人埼玉医科大学 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
WO2011072091A1 (en) * 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US20130253168A1 (en) * 2010-08-31 2013-09-26 Steven L. Colletti Novel single chemical entities and methods for delivery of oligonucleotides
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US9663784B2 (en) * 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
BR112015013105B1 (pt) * 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
US10004814B2 (en) * 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
TWI864340B (zh) * 2014-10-10 2024-12-01 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
TWI769565B (zh) * 2014-11-10 2022-07-01 美商阿尼拉製藥公司 B型肝炎病毒(HBV)iRNA組成物及其用途方法
EP3362562B1 (en) * 2015-10-16 2026-07-22 Academisch Ziekenhuis Leiden, also acting under the name Leiden University Medical Centre (LUMC) Antisense oligonucleotides for use in treating alzheimer's disease
CA3098623A1 (en) * 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
JP7557469B2 (ja) * 2019-01-29 2024-09-27 アイオーニス ファーマシューティカルズ, インコーポレーテッド Appの発現を低減するための化合物及び方法
EP3983077A4 (en) * 2019-06-17 2023-12-20 Alnylam Pharmaceuticals, Inc. DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM

Similar Documents

Publication Publication Date Title
CN113454222B (zh) 淀粉样前体蛋白(APP)RNAi剂组成物及其使用方法
TWI727917B (zh) TMPRSS6iRNA 組成物及其使用方法
CN115397436B (zh) 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
JP7863095B2 (ja) Snca関連神経変性疾患を治療又は予防するためのsnca irna組成物及びその使用方法
TW201726148A (zh) 治療serpinc1相關疾患之方法及組成物
TW201718855A (zh) 甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關疾病之使用方法
EA035756B1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
KR20220069103A (ko) 최소 플루오린 함량을 갖는 작은 간섭 rna의 화학적 변형
JP2023523993A5 (cg-RX-API-DMAC7.html)
JP2024536811A5 (cg-RX-API-DMAC7.html)
JP2022520986A5 (cg-RX-API-DMAC7.html)
TW202132567A (zh) 亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
WO2023116607A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2024528503A5 (cg-RX-API-DMAC7.html)
JP2023544413A5 (cg-RX-API-DMAC7.html)
JP2023511434A5 (cg-RX-API-DMAC7.html)
IL294728A (en) lrrk2 RNA material preparations and methods of using them
JP2024522068A5 (cg-RX-API-DMAC7.html)
TW202400193A (zh) 抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法
TW202305134A (zh) 杭丁頓蛋白(HTT)iRNA劑組成物及其使用方法
JP2024521907A5 (cg-RX-API-DMAC7.html)
TW202330920A (zh) 用於調節apoc3表現之組合物及方法
CN117561334A (zh) 人染色体9开放阅读框72(C9ORF72)iRNA药剂组合物和其使用方法
KR20200127008A (ko) 담관 부족-연관된 상태의 치료를 위한 방법 및 조성물
WO2021157730A1 (ja) 核酸医薬とその使用